

Special Issue

Update on Allergic Contact Dermatitis: Pathology, Therapy, Comorbidities and New Allergens

Message from the Guest Editor

This Special Issue aims to collate the latest advances in understanding and managing allergic contact dermatitis (ACD), a prevalent and complex skin condition with significant individual and societal impact. This Special Issue aims to publish cutting-edge research in immunopathology, delve into the emerging field of comorbidities, and highlight novel allergens with increasing clinical importance. Contributions that provide insights into innovative diagnostic techniques, therapeutic approaches, and the broader implications of ACD are particularly welcome to be submitted. In particular, we are seeking original articles, reviews, and case reports that advance the field and inspire new directions in research and clinical practice.

- allergic contact dermatitis
- immunopathology
- comorbidities
- emerging allergens
- patch testing
- occupational dermatology
- microbiome and skin
- prevention strategies
- biomarkers in dermatology
- novel therapies for ACD
- quality of life
- epidemiology of ACD
- pediatric dermatology
- environmental allergens
- skin immunology

Guest Editor

Dr. Francisco José Navarro-Triviño

Contact Eczema and Immunoallergic Diseases, Dermatology
Department, Hospital Universitario San Cecilio, Avda. del Conocimiento
s/n, 18016 Granada, Spain

Deadline for manuscript submissions

31 December 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/228447

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).